Table of Contents Chapter 1 Overview of Plasma-derived Immune Inhibitor 1.1 Definition of Plasma-derived Immune Inhibitor in This Report 1.2 Commercial Types of Plasma-derived Immune Inhibitor 1.2.1 Blood Products 1.2.2 Non Plasma Derived Coagulation Factor 1.3 Downstream Application of Plasma-derived Immune Inhibitor 1.3.1 Hospital 1.3.2 Medical Center 1.3.3 Others 1.4 Development History of Plasma-derived Immune Inhibitor 1.5 Market Status and Trend of Plasma-derived Immune Inhibitor 2013-2023 1.5.1 Global Plasma-derived Immune Inhibitor Market Status and Trend 2013-2023 1.5.2 Regional Plasma-derived Immune Inhibitor Market Status and Trend 2013-2023 Chapter 2 Global Market Status and Forecast by Regions 2.1 Market Development of Plasma-derived Immune Inhibitor 2013-2017 2.2 Sales Market of Plasma-derived Immune Inhibitor by Regions 2.2.1 Sales Volume of Plasma-derived Immune Inhibitor by Regions 2.2.2 Sales Value of Plasma-derived Immune Inhibitor by Regions 2.3 Production Market of Plasma-derived Immune Inhibitor by Regions 2.4 Global Market Forecast of Plasma-derived Immune Inhibitor 2018-2023 2.4.1 Global Market Forecast of Plasma-derived Immune Inhibitor 2018-2023 2.4.2 Market Forecast of Plasma-derived Immune Inhibitor by Regions 2018-2023 Chapter 3 Global Market Status and Forecast by Types 3.1 Sales Volume of Plasma-derived Immune Inhibitor by Types 3.2 Sales Value of Plasma-derived Immune Inhibitor by Types 3.3 Market Forecast of Plasma-derived Immune Inhibitor by Types Chapter 4 Global Market Status and Forecast by Downstream Industry 4.1 Global Sales Volume of Plasma-derived Immune Inhibitor by Downstream Industry 4.2 Global Market Forecast of Plasma-derived Immune Inhibitor by Downstream Industry Chapter 5 North America Market Status by Countries, Type, Manufacturers and Downstream Industry 5.1 North America Plasma-derived Immune Inhibitor Market Status by Countries 5.1.1 North America Plasma-derived Immune Inhibitor Sales by Countries (2013-2017) 5.1.2 North America Plasma-derived Immune Inhibitor Revenue by Countries (2013-2017) 5.1.3 United States Plasma-derived Immune Inhibitor Market Status (2013-2017) 5.1.4 Canada Plasma-derived Immune Inhibitor Market Status (2013-2017) 5.1.5 Mexico Plasma-derived Immune Inhibitor Market Status (2013-2017) 5.2 North America Plasma-derived Immune Inhibitor Market Status by Manufacturers 5.3 North America Plasma-derived Immune Inhibitor Market Status by Type (2013-2017) 5.3.1 North America Plasma-derived Immune Inhibitor Sales by Type (2013-2017) 5.3.2 North America Plasma-derived Immune Inhibitor Revenue by Type (2013-2017) 5.4 North America Plasma-derived Immune Inhibitor Market Status by Downstream Industry (2013-2017) Chapter 6 Europe Market Status by Countries, Type, Manufacturers and Downstream Industry 6.1 Europe Plasma-derived Immune Inhibitor Market Status by Countries 6.1.1 Europe Plasma-derived Immune Inhibitor Sales by Countries (2013-2017) 6.1.2 Europe Plasma-derived Immune Inhibitor Revenue by Countries (2013-2017) 6.1.3 Germany Plasma-derived Immune Inhibitor Market Status (2013-2017) 6.1.4 UK Plasma-derived Immune Inhibitor Market Status (2013-2017) 6.1.5 France Plasma-derived Immune Inhibitor Market Status (2013-2017) 6.1.6 Italy Plasma-derived Immune Inhibitor Market Status (2013-2017) 6.1.7 Russia Plasma-derived Immune Inhibitor Market Status (2013-2017) 6.1.8 Spain Plasma-derived Immune Inhibitor Market Status (2013-2017) 6.1.9 Benelux Plasma-derived Immune Inhibitor Market Status (2013-2017) 6.2 Europe Plasma-derived Immune Inhibitor Market Status by Manufacturers 6.3 Europe Plasma-derived Immune Inhibitor Market Status by Type (2013-2017) 6.3.1 Europe Plasma-derived Immune Inhibitor Sales by Type (2013-2017) 6.3.2 Europe Plasma-derived Immune Inhibitor Revenue by Type (2013-2017) 6.4 Europe Plasma-derived Immune Inhibitor Market Status by Downstream Industry (2013-2017) Chapter 7 Asia Pacific Market Status by Countries, Type, Manufacturers and Downstream Industry 7.1 Asia Pacific Plasma-derived Immune Inhibitor Market Status by Countries 7.1.1 Asia Pacific Plasma-derived Immune Inhibitor Sales by Countries (2013-2017) 7.1.2 Asia Pacific Plasma-derived Immune Inhibitor Revenue by Countries (2013-2017) 7.1.3 China Plasma-derived Immune Inhibitor Market Status (2013-2017) 7.1.4 Japan Plasma-derived Immune Inhibitor Market Status (2013-2017) 7.1.5 India Plasma-derived Immune Inhibitor Market Status (2013-2017) 7.1.6 Southeast Asia Plasma-derived Immune Inhibitor Market Status (2013-2017) 7.1.7 Australia Plasma-derived Immune Inhibitor Market Status (2013-2017) 7.2 Asia Pacific Plasma-derived Immune Inhibitor Market Status by Manufacturers 7.3 Asia Pacific Plasma-derived Immune Inhibitor Market Status by Type (2013-2017) 7.3.1 Asia Pacific Plasma-derived Immune Inhibitor Sales by Type (2013-2017) 7.3.2 Asia Pacific Plasma-derived Immune Inhibitor Revenue by Type (2013-2017) 7.4 Asia Pacific Plasma-derived Immune Inhibitor Market Status by Downstream Industry (2013-2017) Chapter 8 Latin America Market Status by Countries, Type, Manufacturers and Downstream Industry 8.1 Latin America Plasma-derived Immune Inhibitor Market Status by Countries 8.1.1 Latin America Plasma-derived Immune Inhibitor Sales by Countries (2013-2017) 8.1.2 Latin America Plasma-derived Immune Inhibitor Revenue by Countries (2013-2017) 8.1.3 Brazil Plasma-derived Immune Inhibitor Market Status (2013-2017) 8.1.4 Argentina Plasma-derived Immune Inhibitor Market Status (2013-2017) 8.1.5 Colombia Plasma-derived Immune Inhibitor Market Status (2013-2017) 8.2 Latin America Plasma-derived Immune Inhibitor Market Status by Manufacturers 8.3 Latin America Plasma-derived Immune Inhibitor Market Status by Type (2013-2017) 8.3.1 Latin America Plasma-derived Immune Inhibitor Sales by Type (2013-2017) 8.3.2 Latin America Plasma-derived Immune Inhibitor Revenue by Type (2013-2017) 8.4 Latin America Plasma-derived Immune Inhibitor Market Status by Downstream Industry (2013-2017) Chapter 9 Middle East and Africa Market Status by Countries, Type, Manufacturers and Downstream Industry 9.1 Middle East and Africa Plasma-derived Immune Inhibitor Market Status by Countries 9.1.1 Middle East and Africa Plasma-derived Immune Inhibitor Sales by Countries (2013-2017) 9.1.2 Middle East and Africa Plasma-derived Immune Inhibitor Revenue by Countries (2013-2017) 9.1.3 Middle East Plasma-derived Immune Inhibitor Market Status (2013-2017) 9.1.4 Africa Plasma-derived Immune Inhibitor Market Status (2013-2017) 9.2 Middle East and Africa Plasma-derived Immune Inhibitor Market Status by Manufacturers 9.3 Middle East and Africa Plasma-derived Immune Inhibitor Market Status by Type (2013-2017) 9.3.1 Middle East and Africa Plasma-derived Immune Inhibitor Sales by Type (2013-2017) 9.3.2 Middle East and Africa Plasma-derived Immune Inhibitor Revenue by Type (2013-2017) 9.4 Middle East and Africa Plasma-derived Immune Inhibitor Market Status by Downstream Industry (2013-2017) Chapter 10 Market Driving Factor Analysis of Plasma-derived Immune Inhibitor 10.1 Global Economy Situation and Trend Overview 10.2 Plasma-derived Immune Inhibitor Downstream Industry Situation and Trend Overview Chapter 11 Plasma-derived Immune Inhibitor Market Competition Status by Major Manufacturers 11.1 Production Volume of Plasma-derived Immune Inhibitor by Major Manufacturers 11.2 Production Value of Plasma-derived Immune Inhibitor by Major Manufacturers 11.3 Basic Information of Plasma-derived Immune Inhibitor by Major Manufacturers 11.3.1 Headquarters Location and Established Time of Plasma-derived Immune Inhibitor Major Manufacturer 11.3.2 Employees and Revenue Level of Plasma-derived Immune Inhibitor Major Manufacturer 11.4 Market Competition News and Trend 11.4.1 Merger, Consolidation or Acquisition News 11.4.2 Investment or Disinvestment News 11.4.3 New Product Development and Launch Chapter 12 Plasma-derived Immune Inhibitor Major Manufacturers Introduction and Market Data 12.1 GSK 12.1.1 Company profile 12.1.2 Representative Plasma-derived Immune Inhibitor Product 12.1.3 Plasma-derived Immune Inhibitor Sales, Revenue, Price and Gross Margin of GSK 12.2 Merck 12.2.1 Company profile 12.2.2 Representative Plasma-derived Immune Inhibitor Product 12.2.3 Plasma-derived Immune Inhibitor Sales, Revenue, Price and Gross Margin of Merck 12.3 Sanofi 12.3.1 Company profile 12.3.2 Representative Plasma-derived Immune Inhibitor Product 12.3.3 Plasma-derived Immune Inhibitor Sales, Revenue, Price and Gross Margin of Sanofi 12.4 Bayer 12.4.1 Company profile 12.4.2 Representative Plasma-derived Immune Inhibitor Product 12.4.3 Plasma-derived Immune Inhibitor Sales, Revenue, Price and Gross Margin of Bayer Chapter 13 Upstream and Downstream Market Analysis of Plasma-derived Immune Inhibitor 13.1 Industry Chain of Plasma-derived Immune Inhibitor 13.2 Upstream Market and Representative Companies Analysis 13.3 Downstream Market and Representative Companies Analysis Chapter 14 Cost and Gross Margin Analysis of Plasma-derived Immune Inhibitor 14.1 Cost Structure Analysis of Plasma-derived Immune Inhibitor 14.2 Raw Materials Cost Analysis of Plasma-derived Immune Inhibitor 14.3 Labor Cost Analysis of Plasma-derived Immune Inhibitor 14.4 Manufacturing Expenses Analysis of Plasma-derived Immune Inhibitor Chapter 15 Report Conclusion Chapter 16 Research Methodology and Reference 16.1 Methodology/Research Approach 16.1.1 Research Programs/Design 16.1.2 Market Size Estimation 16.1.3 Market Breakdown and Data Triangulation 16.2 Data Source 16.2.1 Secondary Sources 16.2.2 Primary Sources 16.3 Reference

List of Tables Table Advantage and Disadvantage of Blood Products Table Advantage and Disadvantage of Non Plasma Derived Coagulation Factor Table Sales Volume of Plasma-derived Immune Inhibitor by Regions 2013-2017 Table Sales Value of Plasma-derived Immune Inhibitor by Regions 2013-2017 Table Production Volume of Plasma-derived Immune Inhibitor by Regions 2013-2017 Table Global Sales Volume of Plasma-derived Immune Inhibitor by Regions 2018-2023 Table Global Sales Value of Plasma-derived Immune Inhibitor by Regions 2018-2023 Table Global Production Volume of Plasma-derived Immune Inhibitor by Regions 2018-2023 Table Sales Volume of Plasma-derived Immune Inhibitor by Types 2013-2017 Table Sales Value of Plasma-derived Immune Inhibitor by Types 2013-2017 Table Sales Volume Forecast of Plasma-derived Immune Inhibitor by Types 2018-2023 Table Sales Value Forecast of Plasma-derived Immune Inhibitor by Types 2018-2023 Table Sales Volume of Plasma-derived Immune Inhibitor by Downstream Industry 2013-2017 Table Sales Volume Forecast of Plasma-derived Immune Inhibitor by Downstream Industry 2018-2023 Table North America Plasma-derived Immune Inhibitor Sales by Countries (2013-2017) Table North America Plasma-derived Immune Inhibitor Sales Share by Countries (2013-2017) Table North America Plasma-derived Immune Inhibitor Revenue by Countries (2013-2017) Table North America Plasma-derived Immune Inhibitor Revenue Market Share by Countries (2013-2017) Table North America Plasma-derived Immune Inhibitor Sales by Type (2013-2017) Table North America Plasma-derived Immune Inhibitor Sales Share by Type (2013-2017) Table North America Plasma-derived Immune Inhibitor Revenue by Type (2013-2017) Table North America Plasma-derived Immune Inhibitor Revenue Share by Type (2013-2017) Table North America Plasma-derived Immune Inhibitor Sales by Downstream Industry (2013-2017) Table North America Plasma-derived Immune Inhibitor Sales Share by Downstream Industry (2013-2017) Table Europe Plasma-derived Immune Inhibitor Sales by Countries (2013-2017) Table Europe Plasma-derived Immune Inhibitor Sales Share by Countries (2013-2017) Table Europe Plasma-derived Immune Inhibitor Revenue by Countries (2013-2017) Table Europe Plasma-derived Immune Inhibitor Revenue Market Share by Countries (2013-2017) Table Europe Plasma-derived Immune Inhibitor Sales by Type (2013-2017) Table Europe Plasma-derived Immune Inhibitor Sales Share by Type (2013-2017) Table Europe Plasma-derived Immune Inhibitor Revenue by Type (2013-2017) Table Europe Plasma-derived Immune Inhibitor Revenue Share by Type (2013-2017) Table Europe Plasma-derived Immune Inhibitor Sales by Downstream Industry (2013-2017) Table Europe Plasma-derived Immune Inhibitor Sales Share by Downstream Industry (2013-2017) Table Asia Pacific Plasma-derived Immune Inhibitor Sales by Countries (2013-2017) Table Asia Pacific Plasma-derived Immune Inhibitor Sales Share by Countries (2013-2017) Table Asia Pacific Plasma-derived Immune Inhibitor Revenue by Countries (2013-2017) Table Asia Pacific Plasma-derived Immune Inhibitor Revenue Market Share by Countries (2013-2017) Table Asia Pacific Plasma-derived Immune Inhibitor Sales by Type (2013-2017) Table Asia Pacific Plasma-derived Immune Inhibitor Sales Share by Type (2013-2017) Table Asia Pacific Plasma-derived Immune Inhibitor Revenue by Type (2013-2017) Table Asia Pacific Plasma-derived Immune Inhibitor Revenue Share by Type (2013-2017) Table Asia Pacific Plasma-derived Immune Inhibitor Sales by Downstream Industry (2013-2017) Table Asia Pacific Plasma-derived Immune Inhibitor Sales Share by Downstream Industry (2013-2017) Table Latin America Plasma-derived Immune Inhibitor Sales by Countries (2013-2017) Table Latin America Plasma-derived Immune Inhibitor Sales Share by Countries (2013-2017) Table Latin America Plasma-derived Immune Inhibitor Revenue by Countries (2013-2017) Table Latin America Plasma-derived Immune Inhibitor Revenue Market Share by Countries (2013-2017) Table Latin America Plasma-derived Immune Inhibitor Sales by Type (2013-2017) Table Latin America Plasma-derived Immune Inhibitor Sales Share by Type (2013-2017) Table Latin America Plasma-derived Immune Inhibitor Revenue by Type (2013-2017) Table Latin America Plasma-derived Immune Inhibitor Revenue Share by Type (2013-2017) Table Latin America Plasma-derived Immune Inhibitor Sales by Downstream Industry (2013-2017) Table Latin America Plasma-derived Immune Inhibitor Sales Share by Downstream Industry (2013-2017) Table Middle East and Africa Plasma-derived Immune Inhibitor Sales by Regions (2013-2017) Table Middle East and Africa Plasma-derived Immune Inhibitor Sales Share by Regions (2013-2017) Table Middle East and Africa Plasma-derived Immune Inhibitor Revenue by Regions (2013-2017) Table Middle East and Africa Plasma-derived Immune Inhibitor Revenue Market Share by Regions (2013-2017) Table Middle East and Africa Plasma-derived Immune Inhibitor Sales by Type (2013-2017) Table Middle East and Africa Plasma-derived Immune Inhibitor Sales Share by Type (2013-2017) Table Middle East and Africa Plasma-derived Immune Inhibitor Revenue by Type (2013-2017) Table Middle East and Africa Plasma-derived Immune Inhibitor Revenue Share by Type (2013-2017) Table Middle East and Africa Plasma-derived Immune Inhibitor Sales by Downstream Industry (2013-2017) Table Middle East and Africa Plasma-derived Immune Inhibitor Sales Share by Downstream Industry (2013-2017) Table Production Volume of Plasma-derived Immune Inhibitor by Major Manufacturers 2013-2017 Table Production Value of Plasma-derived Immune Inhibitor by Major Manufacturers 2013-2017 Table Headquarters Location and Established Time of Plasma-derived Immune Inhibitor Major Manufacturer Table Employees and Revenue Level of Plasma-derived Immune Inhibitor Major Manufacturer Table Representative Plasma-derived Immune Inhibitor Product One of GSK Table Representative Plasma-derived Immune Inhibitor Product Two of GSK Table Plasma-derived Immune Inhibitor Sales, Revenue, Price and Gross Margin of GSK 2013-2017 Table Representative Plasma-derived Immune Inhibitor Product One of Merck Table Representative Plasma-derived Immune Inhibitor Product Two of Merck Table Plasma-derived Immune Inhibitor Sales, Revenue, Price and Gross Margin of Merck 2013-2017 Table Representative Plasma-derived Immune Inhibitor Product One of Sanofi Table Representative Plasma-derived Immune Inhibitor Product Two of Sanofi Table Plasma-derived Immune Inhibitor Sales, Revenue, Price and Gross Margin of Sanofi 2013-2017 Table Representative Plasma-derived Immune Inhibitor Product One of Bayer Table Representative Plasma-derived Immune Inhibitor Product Two of Bayer Table Plasma-derived Immune Inhibitor Sales, Revenue, Price and Gross Margin of Bayer 2013-2017